about 1%-2% of patients with chronic refractory pouchitis, in the context of ulcerative colitis, end up with a permanent ileostomy. The aim of this systematic review was to collect all published studies involving patients treated with vedolizumab for chronic refractory or antibiotic-dependent pouchitis and then pool the data regarding the effectiveness of this therapeutic strategy.
Vedolizumab for treatment of chronic refractory pouchitis: a systematic review with pool analysis
Ribaldone, Davide Giuseppe;Pellicano, Rinaldo;Saracco, Giorgio Maria;Morino, Mario;
2020-01-01
Abstract
about 1%-2% of patients with chronic refractory pouchitis, in the context of ulcerative colitis, end up with a permanent ileostomy. The aim of this systematic review was to collect all published studies involving patients treated with vedolizumab for chronic refractory or antibiotic-dependent pouchitis and then pool the data regarding the effectiveness of this therapeutic strategy.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
ArticuloDOI_6336.pdf
Accesso aperto
Tipo di file:
POSTPRINT (VERSIONE FINALE DELL’AUTORE)
Dimensione
541.25 kB
Formato
Adobe PDF
|
541.25 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
